Impact of paraaortic lymphadenectomy for endometrial cancer with positive pelvic lymph nodes: A Korean Radiation Oncology Group study (KROG 13-17)

Yoon, Myung Ha; Park, W.; Huh, Seung Jae; Kim, H.J.; Kim, Y.S.; Kim, Y.B.; Kim, J.-Y.; Lee, J.-H.; Cha, Jae-Young; Kim, J.H.; Kim, Hyoju; Yoon, Won Sup; Choi, Jeongjoon; Chun, Mison; Choi, Yun-Young; Chang, Soo-Ho; Lee, K.K.; Kim, M.; Jeong, Jae Uk; Nam, Taek‐Keun

doi:10.1016/j.ejso.2016.07.003

Cited by 17 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiation is currently recommended for advanced corpus carcinoma with lymph invasion. [ 2 , 3 ] Patients receiving radiation have a significantly reduced recurrence and metastasis rate, and disease-free survival is greater. [ 4 , 5 ] However, side effects of radiation have been widely reported, including impaired fertility, [ 6 ] secondary malignancy, [ 7 , 8 ] and lung metastasis.…”

Section: Introductionmentioning

confidence: 99%

Stard

Mao

Zhao²,

Huang³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Stard

Mao

Zhao²,

Huang³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…The question regarding the therapeutic benefit has long remained unanswered by direct study despite indirect evidence from a SEER analysis by Chan et al demonstrating that the extent of the lymph node dissection by count was directly related to improved OS [27]. The findings of Yoon et al include a significant effect of lymphadenectomy when patients are treated with radiation therapy alone and although there was a trend towards a similar result in those patients receiving chemotherapy and radiation, it did not reach statistical significance [28]. As a practical matter, the inability to identify macroscopic involvement of the retroperitoneal nodes without subjecting patients to additional surgical morbidity, is problematic.…”

Section: Discussionmentioning

confidence: 99%

The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study

Spirtos

Enserro

Homesley

et al. 2019

Gynecologic Oncology

View full text Add to dashboard Cite

Conflicts of interest Dr. Nick Spirtos receives money from a grant to the Women's Cancer Center of Nevada, Inc. and also support for travel to meetings for the study or other purposes. He also receives royalties paid to him regarding Wiley -textbook authorship. Dr. Danielle Enserro receives money to her institution from NCI for Cooperative Group/NCTN Grant Funding for all aspects of this trial, including travel to Group meetings; statistical analysis, study monitoring, etc. She also receives monies from a NCTN Group Funding Grant through NCI, as well as monies from the GOG Foundation, Inc. Dr. David Cella received money from GOG/NRG for support for travel to meetings for the study or other purposes. Dr. Robert Morris served as a consultant for Clovis Oncology and Janssen. Dr. David Miller served as a consultant for Tesaro, Janssen, Clovis and Genentech. His institution also received grant funding through Advenchen, Takeda, Tesaro and Xenetic. He also received monies from Genentech and Clovis for payment for lectures, including service on speakers' bureaus.

show abstract

“…The benefit of lymphadenectomy in EC patients has been a controversial topic for over a decade (12)(13)(14). The survival advantage associated with lymphadenectomy exists primarily in patients with a relatively high risk of recurrence (14)(15)(16)(17)(18), and improperly expanding the indication of lymphadenectomy might result in more adverse effects instead (19)(20)(21)(22)(23)(24)(25). Our research didn't support the role of lymphadenectomy in preventing LNR in terms of the scope and number of LNs harvest, with agreement with Mariani et al (5).…”

Section: Discussionmentioning

confidence: 99%

A detailed analysis of lymph node recurrence in endometrial carcinoma

Li¹,

Dong²,

Dai³

et al. 2022

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: The lymph node (LN) is one of the main sites of recurrence in patients with endometrial carcinoma (EC). Literature specifically analyzing LN recurrence (LNR) in EC remains limited in number.Methods: Patients with EC undergoing surgery between 2006 and 2021 in Peking University People's Hospital was included, clinicopathological data of whom were collected and analyzed retrospectively by R 4.0.3.Results: A total of 792 patients were included, with 73 patients having recurrence, among whom 21 patients had LNR. Median recurrence-free survival (RFS) in patients with LNR was 16 [4-39] months. LNR was extensive, with pelvic LNs most commonly involved (9/21). There are various patterns of LNR, with 33.3% (7/21) LN-only recurrence. Multivariable analysis suggested advanced stage, larger tumor diameter and poor histology were independent risk factors for LNR. Patients with LN metastasis (LNM) diagnosed at initial treatment accounted for 47.6% (10/21) of cases with LNR, 60.0% (6/10) of whom had recurrent LNs beyond the region of LNM, 90.0% (9/10) of whom had recurrence nodes overlapping with the range of lymphadenectomy. Uni-and multi-variable analysis suggested lymphadenectomy was not a protective factor for LNR, with both the range and number of LNs harvested considered.Conclusions: LNR is common in patients with EC, with an extensive range and various patterns of recurrence. The International Federation of Gynecology and Obstetrics (FIGO) stage, tumor diameter and histology were independent risk factors for LNR, but lymphadenectomy seemed not a protective factor for LNR.

show abstract

Impact of paraaortic lymphadenectomy for endometrial cancer with positive pelvic lymph nodes: A Korean Radiation Oncology Group study (KROG 13-17)

Cited by 17 publications

References 15 publications

Stard

Stard

The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study

A detailed analysis of lymph node recurrence in endometrial carcinoma

Contact Info

Product

Resources

About